155
Views
12
CrossRef citations to date
0
Altmetric
Original

Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi

, , , , , , , , & show all
Pages 473-479 | Received 16 Jul 2005, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Gilles A. Salles, Ruth Pettengell, Raul Cordoba, Monika Długosz-Danecka, Wojciech Jurczak & Hervé Tilly. (2019) Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. Leukemia & Lymphoma 60:7, pages 1610-1625.
Read now

Articles from other publishers (11)

Sinem Civriz Bozda?Emre Tekg?nd?z, Gamze Durgun, Abdurrahman Sar?ca, It?r ?irino?lu Demiriz, ?erife Ko?ubaba & Fevzi Altunta?. (2013) Which regimen is better for stem cell mobilization of lymphoma patients?. Transfusion and Apheresis Science 48:3, pages 407-410.
Crossref
John L. Reagan, Alan Rosmarin, James N. Butera, Ahmed Nadeem, Fred J. Schiffman, William M. Sikov, Eric Winer & Anthony E. Mega. (2011) Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL. Cancer Chemotherapy and Pharmacology 68:4, pages 1075-1080.
Crossref
Igor Aurer, Houchingue Eghbali, John Raemaekers, Hussein M. Khaled, Catherine Fortpied, Liliana Baila & Richard W.M. van der Maazen. (2011) Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin’s lymphoma - EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54). European Journal of Haematology 86:2, pages 111-116.
Crossref
Byeong-Bae Park, Won Seog Kim, Hyeon Seok Eom, Jin Seok Kim, Young Yiul Lee, Suk Joong Oh, Dae Ho Lee & Cheolwon Suh. (2009) Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin’s lymphoma: a consortium for improving survival of lymphoma (CISL) trial. Investigational New Drugs 29:1, pages 154-160.
Crossref
PAOLO G. GOBBI, LARA VILLANO, DONATELLA POZZOLI & MANUELA BERGONZI. (2010) Role of conventional salvage multiple-drug chemotherapy in relapsed and refractory aggressive non-Hodgkin lymphomas. Oncology Letters 1:4, pages 679-683.
Crossref
P G Gobbi, F Valentino, P Lambelet, V Perfetti, G Bergamaschi, M Girino & G R Corazza. (2009) Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs. Bone Marrow Transplantation 44:1, pages 19-25.
Crossref
Tara Seshadri, John Kuruvilla, Michael Crump & Armand Keating. (2008) Salvage Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation 14:3, pages 259-267.
Crossref
Yago Nieto, Azucena Aldaz, José Rifón, Javier Pérez-Calvo, Ana Zafra, Laura Zufia, Antonio Viúdez, Santiago Viteri, José Manuel Aramendía, Javier Aristu, Carlos Centeno, Marta Moreno, Onintza Sayar & Milagros Hernández. (2007) Phase I and Pharmacokinetic Study of Gemcitabine Administered at Fixed-Dose Rate, Combined with Docetaxel/Melphalan/Carboplatin, with Autologous Hematopoietic Progenitor-Cell Support, in Patients with Advanced Refractory Tumors. Biology of Blood and Marrow Transplantation 13:11, pages 1324-1337.
Crossref
A Spencer, K Reed & C Arthur. (2007) Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Internal Medicine Journal 0:0, pages 070602000936001-???.
Crossref
Fatih M. Uckun, Sanda Morar & Sanjive Qazi. (2006) Vinorelbine-based salvage chemotherapy for therapy-refractory aggressive leukaemias. British Journal of Haematology 135:4, pages 500-508.
Crossref
. (2006) Current Awareness in Hematological Oncology. Hematological Oncology 24:2, pages 89-96.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.